Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $17.92 USD
Change Today +0.46 / 2.63%
Volume 880.2K
THRX On Other Exchanges
Symbol
Exchange
Munich
NASDAQ GS
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Michael W. Aguiar

Chief Executive Officer, President and Director, Theravance Inc.
AgeTotal Calculated CompensationThis person is connected to 5 board members in 1 different organizations across 1 different industries.

See Board Relationships
48$4,560,128
As of Fiscal Year 2014

Background*

Mr. Michael W. Aguiar, also known as Mike, has been the Chief Executive Officer and President of Theravance Inc., since August 15, 2014. Mr. Aguiar served as the Chief Financial Officer of Theravance Inc since March 7, 2005 and served as its Principal Accounting Officer and Treasurer. He has also been Senior Vice President of Finance at Theravance Inc. since March 7, 2005 and served as Secretary. He served as Vice President of Finance at Gilead Sciences. In his two years ...

Read Full Background

Corporate Headquarters*

951 Gateway Boulevard
South San Francisco, California 94080

United States

Phone: 650-238-9600
Fax: --

Board Members Memberships*

2014-Present
Chief Executive Officer, President and Director

Education*

MBA
University of Michigan
BS
University of California, Irvine

Other Affiliations*

Annual Compensation*

Salary$557,247
Total Annual Compensation$557,247

Stock Options*

Restricted Stock Awards$3,564,881
All Other Compensation$500
Exercisable Options152,033
Total Number of Options152,033

Total Compensation*

Total Annual Cash Compensation$995,247
Total Short Term Compensation$557,247
Other Long Term Compensation$3,565,381
Total Calculated Compensation$4,560,128
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
THRX:US $17.92 USD +0.46

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Howard W. Robin Chief Executive Officer, President and Director
Nektar Therapeutics
$831.2K
Peter M. Hecht Ph.D. Co-Founder, Chief Executive Officer and Director
Ironwood Pharmaceuticals, Inc.
$100.0K
Mark R. Baker J.D.Chief Executive Officer, Director and Member of Science & Strategy Committee
Progenics Pharmaceuticals, Inc.
$535.6K
Peter S. Greenleaf Chief Executive Officer and Director
Sucampo Pharmaceuticals, Inc.
$440.2K
Richard Martin Steeves Ph.D.Group Chief Executive Officer, Member of Senior Executive Board and Executive Director
Synergy Health plc
823.0K GBP
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THERAVANCE INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.